PURPOSE: (11)C-PK11195 is a radiopharmaceutical for in vivo assessment of peripheral benzodiazepine receptor (PBR) activity using PET. We sought to clarify the metabolic fate of (11)C-PK11195 in a test-retest setting using radio-HPLC in comparison with radio-TLC, and the whole-body distribution in humans. MATERIALS AND METHODS: In order to evaluate the reproducibility of radio-HPLC metabolite analyses, ten patients with Alzheimer's disease (AD) underwent two successive (11)C-PK11195 examinations on separate days. For comparison of different analytical methods, plasma samples from seven patients were also analysed by radio-TLC. In addition, we evaluated the whole-body distribution of (11)C-PK11195 and its uptake in the brain. RESULTS: The level of unmetabolized (11)C-PK11195 decreased slowly from 96.3 +/- 1.6% (mean+/-SD) at 5 min to 62.7 +/- 8.3% at 40 min after injection. Large individual variation was observed in the amount of plasma (11)C-PK11195 radiometabolites. The whole-body distribution of (11)C-PK11195 showed the highest radioactivity levels in urinary bladder, adrenal gland, liver, salivary glands, heart, kidneys, and vertebral column. In addition, the hip bone and breast bone were clearly visualized by PET. In patients with AD, (11)C-PK11195 uptake in the brain was the highest in the basal ganglia and thalamus, followed by the cortical grey matter regions and the cerebellum. Low (11)C-PK11195 uptake was observed in the white matter. CONCLUSION: Our results indicate that (11)C-PK11195 is eliminated both through the renal and hepatobiliary systems. Careful analysis of plasma metabolites is required to determine the accurate arterial input function for quantitative PET measurement.
PURPOSE: (11)C-PK11195 is a radiopharmaceutical for in vivo assessment of peripheral benzodiazepine receptor (PBR) activity using PET. We sought to clarify the metabolic fate of (11)C-PK11195 in a test-retest setting using radio-HPLC in comparison with radio-TLC, and the whole-body distribution in humans. MATERIALS AND METHODS: In order to evaluate the reproducibility of radio-HPLC metabolite analyses, ten patients with Alzheimer's disease (AD) underwent two successive (11)C-PK11195 examinations on separate days. For comparison of different analytical methods, plasma samples from seven patients were also analysed by radio-TLC. In addition, we evaluated the whole-body distribution of (11)C-PK11195 and its uptake in the brain. RESULTS: The level of unmetabolized (11)C-PK11195 decreased slowly from 96.3 +/- 1.6% (mean+/-SD) at 5 min to 62.7 +/- 8.3% at 40 min after injection. Large individual variation was observed in the amount of plasma (11)C-PK11195 radiometabolites. The whole-body distribution of (11)C-PK11195 showed the highest radioactivity levels in urinary bladder, adrenal gland, liver, salivary glands, heart, kidneys, and vertebral column. In addition, the hip bone and breast bone were clearly visualized by PET. In patients with AD, (11)C-PK11195 uptake in the brain was the highest in the basal ganglia and thalamus, followed by the cortical grey matter regions and the cerebellum. Low (11)C-PK11195 uptake was observed in the white matter. CONCLUSION: Our results indicate that (11)C-PK11195 is eliminated both through the renal and hepatobiliary systems. Careful analysis of plasma metabolites is required to determine the accurate arterial input function for quantitative PET measurement.
Authors: Vassilios Papadopoulos; Mario Baraldi; Tomás R Guilarte; Thomas B Knudsen; Jean-Jacques Lacapère; Peter Lindemann; Michael D Norenberg; David Nutt; Abraham Weizman; Ming-Rong Zhang; Moshe Gavish Journal: Trends Pharmacol Sci Date: 2006-07-05 Impact factor: 14.819
Authors: Henri N J M Greuter; Patricia L B van Ophemert; Gert Luurtsema; Bart N M van Berckel; Eric J F Franssen; Bert D Windhorst; Adriaan A Lammertsma Journal: Nucl Med Biol Date: 2005-04 Impact factor: 2.408
Authors: Ulrike W Kaunzner; Yeona Kang; Shun Zhang; Eric Morris; Yihao Yao; Sneha Pandya; Sandra M Hurtado Rua; Calvin Park; Kelly M Gillen; Thanh D Nguyen; Yi Wang; David Pitt; Susan A Gauthier Journal: Brain Date: 2019-01-01 Impact factor: 13.501
Authors: Bryan Mackowiak; Linhao Li; Matthew A Welch; Daochuan Li; Jace W Jones; Scott Heyward; Maureen A Kane; Peter W Swaan; Hongbing Wang Journal: Mol Pharmacol Date: 2017-04-25 Impact factor: 4.436
Authors: Akihiro Takano; Balázs Gulyás; Andrea Varrone; Per Karlsson; Nils Sjoholm; Stig Larsson; Cathrine Jonsson; Richard Odh; Richard Sparks; Nabil Al Tawil; Anja Hoffmann; Torsten Zimmermann; Andrea Thiele; Christer Halldin Journal: Eur J Nucl Med Mol Imaging Date: 2011-07-06 Impact factor: 9.236
Authors: Chad Brouwer; Kimberly J Jenko; Sami S Zoghbi; Cheryl L Morse; Robert B Innis; Victor W Pike Journal: Eur J Med Chem Date: 2016-08-25 Impact factor: 6.514
Authors: Pia Afzelius; Ole L Nielsen; Aage Ko Alstrup; Dirk Bender; Páll S Leifsson; Svend B Jensen; Henrik C Schønheyder Journal: Am J Nucl Med Mol Imaging Date: 2016-01-28
Authors: Jussi Hirvonen; Anne Roivainen; Jere Virta; Semi Helin; Kjell Någren; Juha O Rinne Journal: Eur J Nucl Med Mol Imaging Date: 2009-10-28 Impact factor: 9.236